MA43826A - Inhibiteurs substitués de ménine-mll et méthodes d'utilisation - Google Patents

Inhibiteurs substitués de ménine-mll et méthodes d'utilisation

Info

Publication number
MA43826A
MA43826A MA043826A MA43826A MA43826A MA 43826 A MA43826 A MA 43826A MA 043826 A MA043826 A MA 043826A MA 43826 A MA43826 A MA 43826A MA 43826 A MA43826 A MA 43826A
Authority
MA
Morocco
Prior art keywords
menine
mll
substitute
inhibitors
methods
Prior art date
Application number
MA043826A
Other languages
English (en)
Other versions
MA43826B1 (fr
Inventor
Dmitry Borkin
Tomasz Cierpicki
Jolanta Grembecka
Szymon Klossowski
Liansheng Li
Jonathan Pollock
Pingda Ren
Yi Wang
Tao Wu
Original Assignee
Kura Oncology Inc
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kura Oncology Inc, Univ Michigan Regents filed Critical Kura Oncology Inc
Priority claimed from PCT/US2017/022564 external-priority patent/WO2017161028A1/fr
Publication of MA43826A publication Critical patent/MA43826A/fr
Publication of MA43826B1 publication Critical patent/MA43826B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA43826A 2016-03-16 2017-03-15 Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisation MA43826B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309372P 2016-03-16 2016-03-16
PCT/US2017/022564 WO2017161028A1 (fr) 2016-03-16 2017-03-15 Inhibiteurs substitués de ménine-mll et méthodes d'utilisation

Publications (2)

Publication Number Publication Date
MA43826A true MA43826A (fr) 2018-11-28
MA43826B1 MA43826B1 (fr) 2023-07-31

Family

ID=62683542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43826A MA43826B1 (fr) 2016-03-16 2017-03-15 Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisation

Country Status (2)

Country Link
AR (1) AR107891A1 (fr)
MA (1) MA43826B1 (fr)

Also Published As

Publication number Publication date
MA43826B1 (fr) 2023-07-31
AR107891A1 (es) 2018-06-28

Similar Documents

Publication Publication Date Title
MA43823A (fr) Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
HK1259232A1 (zh) Menin-mll的取代抑制劑及其使用方法
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA44991A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
MA43816A (fr) Protéines de liaison inductibles et méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA42542A (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
DK3259253T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
IL267291A (en) Actonucleotidase inhibitors and methods of using them
MA43284A (fr) Composés et leurs méthodes d'utilisation
MA48595A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA49715A (fr) Oligomères et conjugués d'oligomères
MA43385A (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
MA44526A (fr) Oxystérols et leurs méthodes d'utilisation
MA46422A (fr) Oligonucléotides modifiés et méthodes d'utilisation
MA41642A (fr) Variants de protoxine ii et méthodes d'utilisation
MA42118A (fr) Benzamides substitués et leurs méthodes d'utilisation